Alvotech Scores FDA Nod for Interchangeable High-Concentration Biosimilar to Humira
The US Food and Drug Administration (FDA) has granted approval to Iceland-based Alvotech’s (NASDAQ: ALVO)...
Auto-immune
Sanofi’s Dupixent Receives FDA Priority Review for COPD Indication Extension
Sanofi (NASDAQ: SNY), a French multinational pharmaceutical company, announced last week that the US Food...
Pfizer’s Velsipity Approved by European Commission for Moderately to Severely Active Ulcerative Colitis
The European Commission (EC) has granted regulatory approval to Pfizer (NYSE: PFE) for its S1P...
AbbVie Expands Licensing Agreement for Innovative sCAR-T Platform with Scripps Research
AbbVie (NYSE: ABBV) has expanded its collaboration with Scripps Research’s Calibr-Skaggs Institute, securing licensing rights...
CMS Secures NMPA Approval for Clinical Trials of TYK2 Inhibitor CMS-D001 and GnRH Antagonist CMS-D002
China Medical System Holdings Ltd (CMS, HKG: 0867) has announced that it has received clinical...
AbbVie Reports $54.3 Billion in 2023 Revenues Amid Humira Erosion and Segment Variability
AbbVie (NYSE: ABBV) reported revenues of $54.3 billion for 2023, reflecting a 5.9% year-on-year decline...
Chongqing Genrix Biopharmaceutical Gets NMPA Clearance for IL-4Rα mAb Candidate GR1802
Chongqing Genrix Biopharmaceutical Co., Ltd (SHA: 688443), a Chinese biopharmaceutical company, has announced that it...
Inmagene Biopharmaceuticals Secures Exclusive License for HutchMed’s Drug Candidates IMG-007 and IMG-004
HutchMed (China) Ltd (NASDAQ: HCM; HKG: 0013) has announced that Sino-US biotech Inmagene Biopharmaceuticals has...
Dupixent by Sanofi and Regeneron Approved by FDA for Eosinophilic Esophagitis in Younger Pediatric Patients
The US Food and Drug Administration (FDA) has concluded a priority review and granted approval...
IASO Biotherapeutics Secures NMPA Approval for Fucaso in Refractory Myasthenia Gravis
China-based IASO Biotherapeutics has received clinical trial approval from the National Medical Products Administration (NMPA)...
Sanofi’s Dupixent Receives FDA Label Update for Atopic Dermatitis Patients with Hand or Foot Involvement
Sanofi (NASDAQ: SNY) has been granted authorization by the US Food and Drug Administration (FDA)...
Novartis Acquires Calypso Biotech for USD 250 Million to Bolster IL-15 Pipeline
Novartis (NYSE: NVS) has finalized an agreement to acquire Netherlands-based Calypso Biotech, a 2013 spinout...
AbbVie’s Lutikizumab Advances to Phase III for Hidradenitis Suppurativa After Positive Mid-Stage Results
AbbVie (NYSE: ABBV) has announced the progression of lutikizumab to Phase III clinical trials following...
Novartis’s Cosentyx Secures Additional Indication for Psoriatic Arthritis in China
Swiss pharmaceutical giant Novartis (SWX: NOVN) has announced that its drug Cosentyx (secukinumab), which targets...
Thederma’s TAP-1503 Cream Receives Priority Review Status for Pediatric Atopic Dermatitis Treatment in China
The Center for Drug Evaluation (CDE) website has indicated that China-based Thederma’s TAP-1503 cream is...
Genrix Bio Seeks China Approval for New Xeligekimab Use in Axial Spondyloarthritis
Chongqing Genrix Biopharmaceutical Co., Ltd. (SHA: 688443), a biopharmaceutical company based in China, has submitted...
BMS’s Sotyktu, First TYK2 Inhibitor, Hits Chinese Market
US pharmaceutical giant Bristol Myers Squibb (BMS, NYSE: BMY) has announced the market launch of...
JW Therapeutics and 2seventy Bio Ink Exclusive Deal for CAR-T Cell Therapy in Greater China
JW Therapeutics (HKG: 2126), a biopharmaceutical company based in China, has announced an exclusive collaboration...
AbbVie and Alpine Immune Sciences Halt Early Enrollment in Lupus Trial
AbbVie (NYSE: ABBV) and Alpine Immune Sciences (SWX: ALPN) have made the decision to prematurely...
Jiangsu Hengrui Pharmaceuticals Wins NMPA Approvals for SLE and Lymphoma Drug Candidates
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading Chinese pharmaceutical company, has announced that...